Assessing fetal hemoglobin in patients on Tranylcypromine

Assessing fetal hemoglobin in patients on Tranylcypromine - TCP-HbF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41063

Enrollment

Registered

2014-07-07

Start date

2015-01-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary anemia sickle cell disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients who give consent, taking Tranylcypromine for 2 months or longer, prescribed by their attending physician as part of their regular treatment.

Exclusion criteria

Exclusion criteria: Non-compliance; hemophobia.

Design outcomes

Primary

Measure	Time frame
The amount of HbF in peripheral blood. In adults the amount of HbF is normally less than 1% of the total amount of hemoglobin. HbF levels should be increased to at least 3% in order to use the results of this study for the design of a follow-up study investigating the effect of Tranylcypromine on HbF levels in sickle cell disease patients.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results